Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe

NEW YORK, Dec. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe

http://www.reportlinker.com/p01057717/Global-Markets-for-Diabetes-Therapeutics-and-Diagnostics----Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

INTRODUCTIONSTUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes and for devices and instruments used in the diagnosis and monitoring of diabetes. Special emphasis is given to major forces contributing to the vigorous growth of the diabetes market. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2017. These forecasts are based on epidemiological data and projections, as well as on information about R&D trends and differential market potential on a country-by-country basis. Health care policies, demographics, and the wider economic environment are also taken into account.

REASONS FOR DOING THE STUDY

It is widely recognized that the prevalence of the most common type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 diabetes are also on the rise, although to a less spectacular degree. These trends are of great concern, not only to the individuals affected, but also to governments and providers of health care. Indeed, the economic consequences of diabetes are vast, involving not only the direct burden of managing the disease but also the common and often catastrophic complications such as cardiovascular disease, peripheral neuropathy, and blindness.

Prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and health care agencies. The already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and to the suppliers of devices needed for disease monitoring.

Among the information needs of companies in this field is an accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next five years, and the impact of drugs and technical developments now in the pipeline.

SCOPE OF REPORT

This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the diabetes market, discussed both in global terms and in terms of the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on merger and acquisition (M&A) activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.

A comprehensive refresher course on diabetes is provided as an appendix.

MARKET ANALYSES AND FORECASTSThe dimensions of the surging diabetes epidemic can be witnessed in stark outline against previous smaller estimates only a few years back. Increased awareness of this "modern plague" has led naturally to improved and more frequent testing practices. This new awareness has also led to improved treatment compliance by patients. Added to these are the more expensive therapies and increased penetration of continuous glucose monitoring (CGM) approaches, which all combine to build a public health menace of accelerating proportions.

For the purpose of market analyses in this report, the global market is defined as 13 countries which together make up over 80% of the total diabetes universe. These countries are the U.S., Canada, Brazil, Mexico, China, India, Japan, Russia, Germany, France, Italy, Spain and the U.K.

Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories discussed include insulins and oral hypoglycemic agents, devices including blood glucose monitors and accessories, and software aids to self-management of diabetes by patients.

METHODOLOGYPrimary research for this report included interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consisted of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources, critically assessed by BCC.INTENDED AUDIENCEThis report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information with regard to market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background information on the marketplace in which they are operating.INFORMATION SOURCESSources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from health care institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.ANALYST CREDENTIALSPaul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects.TABLE OF CONTENTSCHAPTER 1 INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

MARKET ANALYSES AND FORECASTS 2

METHODOLOGY 2

INTENDED AUDIENCE 2

INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 SUMMARY 5

THE DIABETES MARKET 5

LEADING COMPANIES 5

SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 ($

BILLIONS) 6

SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, 2011-2017 ($ BILLIONS) 6

CHAPTER 3 OVERVIEW 8

DIABETES BASICS 8

STRUCTURE OF THE DIABETES MARKET 8

DRIVERS FOR GROWTH 8

RISING PREVALENCE 8

TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN

MILLIONS) 8

NEW TECHNOLOGY 9

RATE OF MARKET GROWTH 10

CURRENT TREATMENT OF DIABETES 10

INSULIN 10

Insulin Administration Devices 10

ORAL ANTIDIABETIC DRUGS 11

MONITORING DEVICES FOR DIABETES 11

TABLE 2 TOTAL DIABETES MARKET IN 2012 ($ BILLIONS) 11

REGIONAL SEGMENTATION 11

TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%) 12

MARKET GROWTH 12

THE DIABETES INDUSTRY 12

PHARMACEUTICAL COMPANIES 12

MEDICAL DEVICE COMPANIES 13

CHAPTER 4 PRODUCTS AND SUPPLIERS 15

INSULIN 15

HISTORY 15

Bovine and Porcine Insulin 16

Humanized Insulin 16

COMPANIES SUPPLYING INSULIN 17

Eli Lilly 17

Sanofi 17

Novo Nordisk 17

Some Other Suppliers 17

Wockhardt Limited: India 17

BioconB: India 18

Shreya Life Sciences: India 18

Diosynth: the Netherlands 18

TABLE 4 MAJOR BRANDS OF INSULIN 18

INSULIN DELIVERY 19

SYRINGES 19

INSULIN SYRINGE MANUFACTURERS 19

Becton Dickinson 19

Owen Mumford 20

Terumo 20

B. Braun 20

PENS 20

TABLE 5 INSULIN PENS 21

MANUFACTURERS OF INSULIN PENS 21

Novo Nordisk 21

Owen Mumford 22

Other Makers 22

INJECTORS 22

INJECTOR MANUFACTURERS 23

Activa Brand Products 23

Antares Pharma 23

Bioject 23

MediCool Inc. 23

Owen Mumford 24

Palco Labs Inc. 24

Rosch AG Medizintechnik 24

INSULIN PUMPS 24

What Is an Insulin Pump? 24

The Infusion Set 25

Candidates for Pump Therapy 25

COMPANIES SUPPLYING INSULIN PUMPS 26

Animas Corp. 26

Sooil Development Co. 27

Medtronic MiniMed 27

Nipro Diabetes Systems 27

Roche Insulin Delivery Systems 27

Insulet 27

Tandem Diabetes Care 28

TABLE 6 INSULIN PUMPS 28

Problems with Pumps-or Users? 28

ORAL HYPOGLYCEMIC DRUGS 29

SULFONYLUREAS 29

TABLE 7 SULFONYLUREAS 29

BIGUANIDES 30

ALPHA-GLUCOSIDASE INHIBITOR 30

GLITAZONES 30

PRANDIAL GLUCOSE REGULATORS 30

GLP-1 ANALOGS; ALSO KNOWN AS INCRETIN MIMETICS 31

AMYLIN MIMETIC 31

TABLE 8 ORAL HYPOGLYCEMICS 32

DIAGNOSIS AND MONITORING 32

THE ROLE OF SELF-MONITORING 32

SMBG Frequency 33

BLOOD GLUCOSE MONITORING DEVICES: SUPPLIERS AND PRODUCTS 33

Lancets 34

TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 34

BLOOD-SAMPLING DEVICES 34

Bayer Diagnostics 34

Becton Dickinson 35

Cell Robotics 35

LifeScan 35

Roche Diagnostics 35

BLOOD GLUCOSE MONITORS 35

77 Elektronika Kft 35

Abbott Laboratories 36

Acon Laboratories Inc. 36

AgaMatrix Inc. 36

Apex Biotechnology Corp. 37

Arkray USA 37

Aventir Biotech LLC 37

Bayer Corp. 37

Belbiosens 38

Diagnostic Devices Inc. 38

Eumed Biotechnology Co. Ltd. 38

GlucoPlus Inc. 38

HMD Bio Medical 38

Health & Life Co. 38

HemoCue AB 39

Home Diagnostics Inc. 39

Hypoguard 39

i-SENS Inc. 39

LifeScan Inc. 39

Medtronic 39

Menarini Diagnostics 40

National Diagnostic Products 40

Novabiomedical Corp. 40

Roche 40

TaiDoc Technology Corp. 41

US Diagnostics Inc. 41

GLUCOSE METER ACCURACY 41

OTHER TESTING APPROACHES 42

HEMOGLOBIN A1C 42

Hemoglobin A1c Meters 42

Hemoglobin A1c Kits 43

SOFTWARE AIDS TO DIABETES MONITORING 44

AIDA On-Line 44

Bayer Care: Blood Sugar Log 44

Body Sigma 44

Dailyrating 44

DiabetEASE 44

Diabetes Assistant 45

Diabetes Homecare Center 45

Ecivon 45

HealthEngage Diabetes 45

Lifeclinic 46

PlasmaGlucose 46

Symcare 46

CHAPTER 5 NEW DEVELOPMENTS IN DIABETES 48

APPROACHES BASED ON CURRENT TECHNOLOGY 48

NOVEL INSULIN DELIVERY TECHNOLOGY 48

Oral-Lyn 48

Oramed 48

Medingo Micro-Pump Patch 48

Inhaled Insulin 49

Transdermal Approach 49

IMPROVED ORAL ANTIDIABETIC DRUGS 50

Dutogliptin 50

Byetta LAR 50

Lixisenatide 50

NEW DEVELOPMENTS IN GLUCOSE TESTING 51

Continuous Glucose Monitoring (CGM) 51

Reimbursement 52

Noninvasive Monitoring 52

TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING 55

Integrated Testing 56

ARTIFICIAL PANCREAS 57

Roche 57

Abbott 58

Novo Nordisk/LifeScan 58

Animas 58

RADICAL APPROACHES 59

ALTERNATIVES TO INSULIN 59

IMMUNOTHERAPY 60

TRANSPLANTATION 60

CELL AND STEM CELL THERAPIES 61

GENE THERAPY 62

Gene Therapy Approaches for Expressing Insulin 62

Gene Therapy Approaches for Immunomodulation 62

Gene Therapy Approaches for Cell-Based Therapies 62

A NEW AGE OF MOBILITY IN DIABETES MANAGEMENT 63

THE IMPACT OF NEW DEVELOPMENTS ON THE DIABETES MARKET 64

CHAPTER 6 THE GLOBAL DIABETES MARKET 67

MARKET COMPONENTS 67

SIZE 67

TABLE 11 GLOBAL DIABETES MARKET, 2011 ($ BILLIONS) 67

GROWTH 68

MARKET ANALYSIS BY PRODUCT CATEGORY 68

INSULINS AND INSULIN DELIVERY DEVICES 68

Major Suppliers 69

TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 ($ MILLIONS) 69

OTHER ANTIDIABETIC DRUGS 69

Major Suppliers 69

TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 ($ MILLIONS) 70

INSULIN PUMPS 70

TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 ($ BILLIONS) 71

MONITORING PRODUCTS 71

Major Suppliers 71

TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%) 71

TRENDS 71

REGIONAL SEGMENTATION 72

TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN

MILLIONS) 72

NATIONAL MARKETS 72

North America 73

TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 ($

BILLIONS) 73

South and Central America 74

TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 ($

BILLIONS) 74

Europe 74

TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 ($

BILLIONS) 75

Asia 75

TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 ($

BILLIONS) 75

CHAPTER 7 THE EUROPEAN MARKET 77

FRANCE 77

VITAL STATISTICS 77

HEALTH AND HEALTH CARE 77

PROVISION OF HEALTH CARE 77

FRANCE'S PHARMACEUTICAL MARKET 78

THE DIABETES MARKET 78

TABLE 21 PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017 (CASES IN MILLIONS) 79

TABLE 22 FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 79

TABLE 23 FRANCE: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 79

GERMANY 79

VITAL STATISTICS 80

HEALTH AND HEALTH CARE 80

PROVISION OF HEALTH CARE 80

GERMANY'S PHARMACEUTICAL MARKET 80

PRICE CONTROLS 81

THE DIABETES MARKET 81

TABLE 24 PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017 (CASES IN MILLIONS) 82

TABLE 25 GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 82

TABLE 26 GERMANY: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 82

ITALY 82

VITAL STATISTICS 82

HEALTH AND HEALTH CARE 83

PROVISION OF HEALTH CARE 83

ITALY'S PHARMACEUTICAL MARKET 83

IMPLICATIONS FOR RESEARCH 85

THE DIABETES MARKET 85

TABLE 27 PREVALENCE OF DIABETES IN ITALY, THROUGH 2017 (CASES IN MILLIONS) 86

TABLE 28 ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 86

TABLE 29 ITALY: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 86

RUSSIA 86

VITAL STATISTICS 86

HEALTH AND HEALTH CARE 87

PROVISION OF HEALTH CARE 87

RUSSIA'S PHARMACEUTICAL MARKET 87

PHARMA 2020 87

THE DIABETES MARKET 88

TABLE 30 PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017 (CASES IN MILLIONS) 89

TABLE 31 RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 89

TABLE 32 RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 89

SPAIN 89

VITAL STATISTICS 89

HEALTH AND HEALTH CARE 90

PROVISION OF HEALTH CARE 90

PHARMACEUTICAL SERVICES 90

SPAIN'S PHARMACEUTICAL MARKET 91

THE DIABETES MARKET 91

TABLE 33 PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017 (CASES IN MILLIONS) 92

TABLE 34 SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 92

TABLE 35 SPAIN: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 92

THE UNITED KINGDOM 92

VITAL STATISTICS 93

HEALTH AND HEALTH CARE 93

PROVISION OF HEALTH CARE 93

Private Sector Involvement 93

PHARMACEUTICALS 94

THE UNITED KINGDOM'S PHARMACEUTICAL MARKET 94

THE DIABETES MARKET 95

TABLE 36 PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017 (CASES IN MILLIONS) 95

TABLE 37 U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 96

TABLE 38 U.K.: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 96

CHAPTER 8 COMPANY PROFILES 98

LEADING COMPANIES 98

ABBOTT LABORATORIES 98

Overview 98

ABBOTT DIABETES CARE, INC. 99

BAYER AG 99

Overview 99

Diabetes Products 100

BECTON DICKINSON 100

Overview 100

Diabetes Products 101

BRISTOL-MYERS SQUIBB 101

Overview 101

Problems with Generics 101

Diabetes Products 101

Pipeline 102

ELI LILLY AND CO. 102

Overview 102

Diabetes Products 102

Pipeline 103

GLAXO SMITHKLINE 103

Overview 103

Diabetes Products 103

Pipeline 104

JOHNSON & JOHNSON 104

Overview 104

Diabetes Products 104

Pipeline 105

MEDTRONIC 105

Overview 105

Diabetes Products 106

Pipeline 106

MERCK & CO. LTD. 106

Diabetes 107

SmartCells 107

MERCK KGAA 108

Overview 108

Diabetes Products 108

NOVARTIS INTERNATIONAL AG 109

Overview 109

Diabetes Products 109

Research 109

NOVO NORDISK A/S 110

Overview 110

Diabetes Products 110

Pipeline 111

TABLE 39 NOVO NORDISK DIABETES PRODUCT PIPELINE 112

ROCHE 112

Overview 112

Diabetes Products 113

Blood Glucose Monitoring Systems 113

Diabetes Data Management 114

Insulin Pump Systems 114

Lancet Devices 114

Other 115

Pipeline 115

SANOFI 115

Overview 115

Diabetes Products 116

TAKEDA 116

Overview 116

Pipeline 117

TABLE 40 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 117

OTHER COMPANIES 118

77 ELEKTRONIKA CO., LTD. 118

AGAMATRIX, INC. 118

ANIMAS CORP. 119

BIO-IMPEDANCE GENERAL LTD. 119

DEBIOTECH S.A. 120

INLIGHT SOLUTIONS, INC. 120

LIFESCAN, INC. 121

MANNKIND CORP. 121

A. MENARINI DIAGNOSTICS S.R.L. 122

NIPRO CORP. 3-9-3, 122

OWEN MUMFORD LTD. 123

PALCO LABS, INC. 124

PRODIGY DIABETES CARE LLC 124

TERUMO CORP. 125

TRANSITION THERAPEUTICS INC. 125

CHAPTER 9 APPENDIX I: ABOUT DIABETES 127

BLOOD SUGAR REGULATION 127

INSULIN 127

TYPE 1 DIABETES 128

TYPE 2 DIABETES 128

GESTATIONAL DIABETES 129

OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN 129

MATURE-ONSET DIABETES OF THE YOUNG (MODY) 130

OTHER DIABETIC STATES 130

LATENT AUTOIMMUNE DIABETES (LADA) 130

PREDIABETES 130

DIAGNOSIS 131

GLUCOSE TESTS 131

OFFICIAL CRITERIA 131

DIFFERENTIAL DIAGNOSIS 131

TYPE 1 DIABETES 131

TYPE 2 DIABETES 132

CURRENT TREATMENT 132

TYPE 1 DIABETES 132

TYPE 2 DIABETES 132

Sulfonylureas 133

Biguanides 133

Alpha-Glucosidase Inhibitors 133

Glitazones (Thiazolidinediones) 134

Prandial Glucose Regulators 134

Incretin Mimetics 134

Dipeptidyl Peptidase 4 (DPP-4) Inhibitors 134

DIET 134

MONITORING DIABETES 134

BLOOD SUGAR CONTROL 134

THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCTT) 135

GLYCATED HEMOGLOBIN (HBA1C) 136

FRUCTOSAMINE 137

PREVALENCE OF DIABETES 137

TYPE 1 138

TYPE 2 138

DIABETIC COMPLICATIONS 138

RETINOPATHY 139

NEUROPATHY 139

NEPHROPATHY 140

INCREASED MORTALITY RISK 140

METABOLIC SYNDROME 140

CHAPTER 10 APPENDIX 2: GLOSSARY 143

TABLE 41 GLOSSARY 143

LIST OF TABLES

SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 ($BILLIONS) 6TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES INMILLIONS) 8TABLE 2 TOTAL DIABETES MARKET IN 2012 ($ BILLIONS) 11TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%) 12TABLE 4 MAJOR BRANDS OF INSULIN 18TABLE 5 INSULIN PENS 21TABLE 6 INSULIN PUMPS 28TABLE 7 SULFONYLUREAS 29TABLE 8 ORAL HYPOGLYCEMICS 32TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 34TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING 55TABLE 11 GLOBAL DIABETES MARKET, 2011 ($ BILLIONS) 67TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 ($ MILLIONS) 69TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 ($ MILLIONS) 70TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 ($ BILLIONS) 71TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%) 71TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES INMILLIONS) 72TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 ($BILLIONS) 73TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 ($ BILLIONS) 74TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 ($BILLIONS) 75TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 ($BILLIONS) 75TABLE 21 PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017 (CASES IN MILLIONS) 79TABLE 22 FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 79TABLE 23 FRANCE: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 79TABLE 24 PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017 (CASES IN MILLIONS) 82TABLE 25 GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 82TABLE 26 GERMANY: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 82TABLE 27 PREVALENCE OF DIABETES IN ITALY, THROUGH 2017 (CASES IN MILLIONS) 86TABLE 28 ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 86TABLE 29 ITALY: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 86TABLE 30 PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017 (CASES IN MILLIONS) 89TABLE 31 RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 89TABLE 32 RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 89TABLE 33 PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017 (CASES IN MILLIONS) 92TABLE 34 SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 92TABLE 35 SPAIN: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 92TABLE 36 PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017 (CASES IN MILLIONS) 95TABLE 37 U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 96TABLE 38 U.K.: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 96TABLE 39 NOVO NORDISK DIABETES PRODUCT PIPELINE 112TABLE 40 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 117TABLE 41 GLOSSARY 143

LIST OF FIGURES

SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, 2011-2017 ($ BILLIONS) 6

To order this report:Pathology Industry: Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe

Contact
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Source: http://news.yahoo.com/global-markets-diabetes-therapeutics-diagnostics-140900590.html

super bowl halftime show 2012 ahmad bradshaw halftime super bowl 2012 super bowl score madonna super bowl performance superbowl commercials best superbowl commercials